Compare MEG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | EVO |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Germany |
| Employees | 3500 | 4553 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 1.1B |
| IPO Year | 2020 | N/A |
| Metric | MEG | EVO |
|---|---|---|
| Price | $22.14 | $3.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $35.25 | $7.00 |
| AVG Volume (30 Days) | ★ 266.4K | 47.1K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $830,538,000.00 | N/A |
| Revenue This Year | $5.41 | $1.37 |
| Revenue Next Year | $7.19 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.26 | N/A |
| 52 Week Low | $19.38 | $2.31 |
| 52 Week High | $32.00 | $4.42 |
| Indicator | MEG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 56.03 |
| Support Level | $20.80 | $2.88 |
| Resistance Level | $23.48 | $3.75 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 88.92 | 89.58 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.